ArticleBioorganic & medicinal chemistry2008
Synthesis and in vitro evaluation of a library of modified endomorphin 1 peptides.
Article in Bioorganic & medicinal chemistry, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 50 citations in OpenAlex.
- Rational Design of Putative Dual-Target Opioid-Dopaminergic Casomorphin-Ranatensin Hybrid Peptides: Computational Modeling and Preliminary Antiproliferative Evaluation.Molecules (Basel, Switzerland) · 2026Article
- Combining flavin photocatalysis with parallel synthesis: a general platform to optimize peptides with non-proteinogenic amino acids.Chemical science · 2021Article
- Caco-2 Cell Permeability of Flavonoids and Saponins fromACS omega · 2020Article
- Food-Derived Hemorphins Cross Intestinal and Blood-Brain BarriersFrontiers in endocrinology · 2018Article
- Stability, permeability and growth-inhibitory properties of gonadotropin-releasing hormone liposaccharides.Pharmaceutical research · 2015Article
- Design, synthesis and characterisation of mannosylated ovalbumin lipid core peptide self-adjuvanting vaccine delivery system.Drug delivery and translational research · 2014Article
- A drug delivery strategy: binding enkephalin to asialoglycoprotein receptor by enzymatic galactosylation.PloS one · 2014Article
- Lipid- and sugar-modified endomorphins: novel targets for the treatment of neuropathic pain.Frontiers in pharmacology · 2013Review
- Biological active analogues of the opioid peptide biphalin: mixed α/β(3)-peptides.Journal of medicinal chemistry · 2013Article
- Lipo-endomorphin-1 derivatives with systemic activity against neuropathic pain without producing constipation.PloS one · 2012Article
- Engineering endomorphin drugs: state of the art.Expert opinion on therapeutic patents · 2012Review
- Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic.Journal of medicinal chemistry · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
Abstract
Endomorphin 1 (Endo-1=Tyr-Pro-Trp-Phe-NH(2)), an endogenous opioid with high affinity and selectivity for mu-opioid receptors, mediates acute and neuropathic pain in rodents. To overcome metabolic instability and poor membrane permeability, the N- and C-termini of Endo-1 were modified by lipoamino acids (Laa) and/or sugars, and 2',6'-dimethyltyrosine (Dmt) replacement of Tyr. Analogues were assessed for mu-opioid receptor affinity, inhibition of cAMP accumulation, enzymatic stability, and permeability across Caco-2 cell monolayers. C-terminus modification decreased receptor affinity, while N-terminus C8-Laa improved stability and permeability with slight change in receptor affinity. Dmt provided a promising lead compound: [C8Laa-Dmt[1]]-Endo-1 is nine times more stable (t(1/2)=43.5min), >8-fold more permeable in Caco-2 cell monolayers, and exhibits 140-fold greater mu-opioid receptor affinity (K(imu)=0.08nM).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.